廣告
香港股市 已收市
  • 恒指

    18,293.38
    +461.05 (+2.59%)
     
  • 國指

    6,532.63
    +160.85 (+2.52%)
     
  • 上證綜指

    2,971.29
    +0.91 (+0.03%)
     
  • 滬深300

    3,472.40
    +4.23 (+0.12%)
     
  • 美元

    7.8073
    +0.0006 (+0.01%)
     
  • 人民幣

    0.9282
    -0.0009 (-0.10%)
     
  • 道指

    40,000.90
    +247.15 (+0.62%)
     
  • 標普 500

    5,615.35
    +30.81 (+0.55%)
     
  • 納指

    18,398.45
    +115.04 (+0.63%)
     
  • 日圓

    0.0492
    +0.0003 (+0.65%)
     
  • 歐元

    8.5154
    +0.0328 (+0.39%)
     
  • 英鎊

    10.1380
    +0.0580 (+0.58%)
     
  • 紐約期油

    82.21
    -0.41 (-0.50%)
     
  • 金價

    2,416.40
    -5.50 (-0.23%)
     
  • Bitcoin

    57,621.95
    +49.82 (+0.09%)
     
  • CMC Crypto 200

    1,204.39
    +5.82 (+0.49%)
     

Why Merck Stock Is Trading Higher Today

Merck & Co Inc's (NYSE: MRKQ1 sales reached $14.49 billion, down 9% Y/Y, beating the consensus of $13.79 billion.

Excluding Lagevrio (COVID-19 treatment), sales growth was 11%; excluding Lagevrio and the impact of foreign exchange, growth was 15%.

Pharmaceutical sales decreased by 10% to $12.72 billion, primarily due to lower sales in virology, mainly attributable to Lagevrio, and diabetes, partially offset by growth in oncology, vaccines, and hospital acute care.

Lagevrio Q1 sales declined 88% Y/Y to $392 million. Ketruda sales grew 20% to $5.8 billion. Gardasil/Gardasil 9 sales grew 35% to $2.0 billion.

廣告

Adjusted EPS of $1.40 also surpassed the analysts' estimate of $1.32 and declined 35% Y/Y.

View more earnings on MRK

Also Read: Merck Acquires Prometheus Biosciences For $10.8B, Strengthening Its Immunology Pipeline.

Moderna Inc (NASDAQ: MRNA) and Merck's cancer vaccine exhibited positive results against relapse for melanoma patients.

About 79% of high-risk melanoma patients who got the personalized vaccine and Merck's immunotherapy Keytruda were alive and cancer-free at 18 months, compared with about 62% of patients who received immunotherapy alone.

2023 Guidance: Merck has raised and narrowed FY23 adjusted EPS guidance to $6.88-$7.00 compared to prior guidance of $6.80-$6.95 and consensus of $6.91.

Merck anticipates FY23 sales Of $57.7-$58.9 billion compared to previously expected $57.2-$58.7 billion and the consensus of $58.28 billion.

Price Action: MRK shares are up 2.29% at $116.03 during the premarket session on the last check Thursday.

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article Why Merck Stock Is Trading Higher Today originally appeared on Benzinga.com

.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.